Nicotine-degrading enzymes for treating nicotine addiction and nicotine poisoning
AssigneesThe Scripps Research Institute, Antidote Therapeutics, Inc.
InventorsKim D. JANDA, Matt KALNIK, Thomas THISTED
Life of this patent
Estimating the term…
Abstract
Described herein are methods and compositions for treating nicotine addiction, promoting smoking cessation, reducing the risk of relapse of nicotine consumption, and/or treating nicotine poisoning in a subject in need thereof, using a nicotine-degrading enzyme or an expression vector capable of expressing a nicotine-degrading enzyme in vivo.
Claims48
A method of treating nicotine addiction, reducing the risk of relapse of nicotine consumption, or treating nicotine poisoning in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a nicotine-degrading enzyme.
A method of degrading nicotine in vivo in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a nicotine-degrading enzyme.
A method of degrading nicotine in vivo in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an expression vector capable of expressing a nicotine-degrading enzyme in vivo.
A pharmaceutical composition comprising a therapeutically effective amount of a nicotine-degrading enzyme in a pharmaceutically acceptable carrier.
The composition of claim 90, wherein the moiety comprises an antibody Fc domain and/or a peptide moiety that mimicks the properties of polyethylene glycol.
Dependencies are inferred from the claim text.